FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 618.03 +5.53 (0.90%)
Previous Close $612.50    52 Week High $592.36 
Open $607.92    52 Week Low $325.35 
Day High $621.79    P/E 162.21 
Day Low $607.92    EPS $3.81 
Volume 1,279,853       

SANOFI (NASDAQ: SNY) Delayed: 41.60 -0.18 (0.43%)
Previous Close $41.78    52 Week High $44.76 
Open $42.27    52 Week Low $36.81 
Day High $42.47    P/E N/A 
Day Low $41.47    EPS $0.00 
Volume 10,855,605